q 2006 by Taylor & Francis Group, LLC - Developers

More documents

Recommendations

Info

q 2006 by Taylor & Francis Group, LLC
Page 1: q 2006 by Taylor & Francis Group, L
Page 5: q 2006 by Taylor & Francis Group, L
Page 8 and 9: selectivity; (3) the ability to car
Page 10 and 11: grateful to the wonderful people at
Page 13 and 14: Contributors Hamidreza Montazeri Al
Page 15 and 16: Ji Hoon Jeong Department of Pharmac
Page 17 and 18: Jong-Sang Park Department of Chemis
Page 19 and 20: Table of Contents Section 1 Nanotec
Page 21 and 22: Chapter 21 Combined Cancer Therapy
Page 23 and 24: 1 CONTENT Introduction and Rational
Page 25 and 26: Introduction and Rationale for Nano
Page 31 and 32: 2 CONTENTS Passive Targeting of Sol
Page 33 and 34: Passive Targeting of Solid Tumors 1
Page 39 and 40: 3 CONTENTS Active Targeting Strateg
Page 41 and 42: Active Targeting Strategies in Canc
Page 53 and 54:
Active Targeting Strategies in Canc
Page 55 and 56:
Page 57 and 58:
Page 59 and 60:
Page 61 and 62:
Page 63 and 64:
4 CONTENTS Pharmacokinetics of Nano
Page 65 and 66:
Pharmacokinetics of Nanocarrier-Med
Page 67 and 68:
Page 69 and 70:
Page 71 and 72:
Page 73 and 74:
Page 75 and 76:
Page 77 and 78:
Page 79 and 80:
5 CONTENTS Multifunctional Nanopart
Page 81 and 82:
Multifunctional Nanoparticles for C
Page 83 and 84:
Page 85 and 86:
(a) (b) 0.03 0.02 Δe 0.01 0.00 q 2
Page 87 and 88:
H 2 N N N NH 2 H CH 3 C HN O 5 HO C
Page 89 and 90:
Page 91 and 92:
Page 93 and 94:
Page 95:
Page 98 and 99:
78 6.8 Other Macromolecules Used fo
Page 100 and 101:
80 (EGF) and the mAb cetuximab (IMC
Page 102 and 103:
82 HO O HO O O O O O O H N S O H N
Page 104 and 105:
84 H 2N Cy5 Cy5 A B G5 G5 G5 Cy5 NH
Page 106 and 107:
86 synthon, a bifunctional carboran
Page 108 and 109:
88 O O H 4 6 8 NH 3 + Cl - 2- (CH 2
Page 110 and 111:
90 A per molecule of mAb was approx
Page 112 and 113:
92 in the cytoplasm, and had high c
Page 114 and 115:
94 in TF-PEG liposomes had a prolon
Page 116 and 117:
96 In conclusion, there is a pletho
Page 118 and 119:
98 Nanotechnology for Cancer Therap
Page 120 and 121:
100 Nanotechnology for Cancer Thera
Page 122 and 123:
Page 125 and 126:
7 CONTENTS Preclinical Characteriza
Page 127 and 128:
Preclinical Characterization of Eng
Page 129 and 130:
Page 131 and 132:
Page 133 and 134:
Page 135 and 136:
Page 137 and 138:
Page 139 and 140:
Page 141 and 142:
Page 143 and 144:
Page 145 and 146:
Page 147 and 148:
Page 149 and 150:
Page 151 and 152:
Page 153 and 154:
Page 155 and 156:
Page 157:
Page 160 and 161:
Page 162 and 163:
Page 164 and 165:
144 costly. The Critical Path Initi
Page 166 and 167:
Page 168 and 169:
Page 170 and 171:
150 At this point, and based on int
Page 172 and 173:
Page 174 and 175:
Page 176 and 177:
Page 178 and 179:
160 endothelial cells. 7-9 Anti-ang
Page 180 and 181:
162 TABLE 9.1 Some Ligands and Thei
Page 182 and 183:
164 Aminopeptidase A (APA) is a hom
Page 184 and 185:
166 cancer. 97 In tumor extract con
Page 186 and 187:
168 9.4 POLYMERIC CONJUGATES FOR AN
Page 188 and 189:
170 was significant inhibition of t
Page 190 and 191:
172 % ID/g (a) % ID/g (b) 16.000 14
Page 192 and 193:
174 conjugates of RGD4C and RGDfK p
Page 194 and 195:
Page 196 and 197:
Page 198 and 199:
Page 200 and 201:
Page 202 and 203:
Page 204 and 205:
186 of normal tissues to the drug.
Page 206 and 207:
188 greater selectivity toward tumo
Page 208 and 209:
Page 210 and 211:
192 side effects, and more convenie
Page 212 and 213:
Page 214 and 215:
196 to meet a number of challenges,
Page 216 and 217:
Page 219 and 220:
11 CONTENTS Noninvasive Visualizati
Page 221 and 222:
Noninvasive Visualization of In Viv
Page 223 and 224:
Page 225 and 226:
Page 227 and 228:
Page 229 and 230:
Page 231 and 232:
12 CONTENTS Polymeric Nanoparticles
Page 233 and 234:
Polymeric Nanoparticles for Tumor-T
Page 235 and 236:
Page 237 and 238:
Page 239 and 240:
Page 241 and 242:
Page 243 and 244:
Page 245:
Page 248 and 249:
232 discontinuous endothelium in th
Page 250 and 251:
234 immunogenicity, have encouraged
Page 252 and 253:
Page 254 and 255:
238 that PEGylated gelatin nanopart
Page 256 and 257:
Page 258 and 259:
Page 260 and 261:
244 above problem of delivery as we
Page 262 and 263:
246 Uptake (μg/mg cell protein) (a
Page 264 and 265:
248 Recently, He et al. have formul
Page 266 and 267:
Page 268 and 269:
252 15.1 CANCER THERAPY Cancer is d
Page 270 and 271:
254 15.2.1.1.2 Emulsion Polymerizat
Page 272 and 273:
256 15.2.1.3 Poly(Alkyl Cyanoacryla
Page 274 and 275:
258 The copolymer poly[aminopoly(et
Page 276 and 277:
260 The molecular weight difference
Page 278 and 279:
Page 280 and 281:
264 in delivering mitoxantrone to t
Page 282 and 283:
266 Golgi apparatus, histiocytes, m
Page 284 and 285:
268 of the adhesive composition has
Page 286 and 287:
270 nucleus nanoparticle P-gp (a) (
Page 288 and 289:
272 both the doxorubicin and the do
Page 290 and 291:
274 15.2.6.4 Drug Delivery to Brain
Page 292 and 293:
276 formation of the doxorubicin-gl
Page 294 and 295:
278 by Loewe et al. 186 using NBCA
Page 296 and 297:
280 15.3 CONCLUSIONS Drug delivery
Page 298 and 299:
Page 300 and 301:
Page 302 and 303:
Page 304 and 305:
Page 306 and 307:
Page 308 and 309:
292 of molecules for targeted deliv
Page 310 and 311:
294 case of isolating DNA aptamers,
Page 312 and 313:
296 16.2.3.6 Cytotoxic T-Cell Antig
Page 314 and 315:
298 16.3.1.2 Polymers for Synthesis
Page 316 and 317:
300 eliminate the need for subseque
Page 318 and 319:
302 3' 5' X 3' 3' X Y 5' 5' X X apt
Page 320 and 321:
304 In addition to small molecule a
Page 322 and 323:
306 16.6 CONCLUSION Bioconjugates c
Page 324 and 325:
Page 326 and 327:
Page 328 and 329:
Page 331 and 332:
17 CONTENTS Polymeric Micelles for
Page 333 and 334:
Polymeric Micelles for Formulation
Page 335 and 336:
Page 337 and 338:
Page 339 and 340:
Page 341 and 342:
Page 343 and 344:
Page 345 and 346:
Page 347 and 348:
Page 349 and 350:
Page 351 and 352:
Page 353 and 354:
Page 355 and 356:
Page 357 and 358:
Page 359 and 360:
Page 361 and 362:
Page 363 and 364:
Page 365 and 366:
Page 367 and 368:
Page 369:
Page 372 and 373:
358 18.1 INTRODUCTION Polymeric mic
Page 374 and 375:
360 (a) (b) R' NH 2 R' NH 2 + R' NH
Page 376 and 377:
362 18.3.1 DIALYSIS METHOD In this
Page 378 and 379:
364 O O PEO-b-P(Asp)-DOX CH3 O CH2
Page 380 and 381:
366 PEO-b -PHSA PEO-b -PBLG PEO-b -
Page 382 and 383:
368 stable and entirely elute as mi
Page 384 and 385:
370 showed similar side effects to
Page 386 and 387:
372 but polymeric micellar formulat
Page 388 and 389:
374 H 2 N H 2 N N H N O N N FOL H N
Page 390 and 391:
376 P(L-Lys)s were further studied
Page 392 and 393:
Page 394 and 395:
Page 396 and 397:
Page 399 and 400:
19 CONTENTS Hydrotropic Polymer Mic
Page 401 and 402:
Hydrotropic Polymer Micelles for Ca
Page 403 and 404:
Page 405 and 406:
Page 407 and 408:
Page 409 and 410:
Page 411 and 412:
Page 413 and 414:
Page 415 and 416:
Page 417 and 418:
Page 419 and 420:
Page 421 and 422:
Page 423 and 424:
20 CONTENTS Tumor-Targeted Delivery
Page 425 and 426:
Tumor-Targeted Delivery of Sparingl
Page 427 and 428:
Page 429 and 430:
Page 431 and 432:
Page 433 and 434:
Page 435 and 436:
21 CONTENTS Combined Cancer Therapy
Page 437 and 438:
Combined Cancer Therapy by Micellar
Page 439 and 440:
Page 441 and 442:
Page 443 and 444:
Page 445 and 446:
Page 447 and 448:
Page 449 and 450:
Page 451 and 452:
Page 453 and 454:
Page 455:
Page 458 and 459:
444 release have been attempted, in
Page 460 and 461:
446 day at room temperature. The po
Page 462 and 463:
448 Intensity (%) (a) 25 20 15 10 5
Page 464 and 465:
450 CMC (μg/ml) 4.0 3.5 3.0 2.5 2.
Page 466 and 467:
452 Cell viability (%) by MTT assay
Page 468 and 469:
454 body weight in experimental gro
Page 470 and 471:
456 Cell Viability (%) by MTT assay
Page 472 and 473:
458 Cell viability (%) by MTT assay
Page 474 and 475:
460 Total DOX (%) in organs This, c
Page 476 and 477:
Page 478 and 479:
Page 480 and 481:
466 Hydrophobic core Hydrated shell
Page 482 and 483:
468 Percentage of cell uptake (a) 1
Page 484 and 485:
470 MRI is another imaging modality
Page 486 and 487:
472 4 nm SPIO DSPE-PEG5k 4 nm SPIO
Page 488 and 489:
474 ACKNOWLEDGMENTS This work was s
Page 491 and 492:
24 CONTENTS Targeted Antisense Olig
Page 493 and 494:
Targeted Antisense Oligonucleotide
Page 495 and 496:
Page 497 and 498:
Page 499 and 500:
Page 501 and 502:
25 CONTENTS Dendrimers as Drug and
Page 503 and 504:
Dendrimers as Drug and Gene Deliver
Page 505 and 506:
Page 507 and 508:
Page 509 and 510:
Page 511 and 512:
Page 513 and 514:
Page 515 and 516:
Page 517 and 518:
Page 519 and 520:
Page 521 and 522:
26 CONTENTS Dendritic Nanostructure
Page 523 and 524:
Dendritic Nanostructures for Cancer
Page 525 and 526:
Page 527 and 528:
Page 529 and 530:
Page 531 and 532:
Page 533:
Page 536 and 537:
524 invasiveness, undifferentiated
Page 538 and 539:
526 ligand Drug Drug Nanosphere Nan
Page 540 and 541:
528 PEG has polyether backbone that
Page 542 and 543:
Page 544 and 545:
532 genomic revolution progresses,
Page 546 and 547:
534 opportunities and solutions to
Page 548 and 549:
536 FIGURE 27.3 Chemical structural
Page 550 and 551:
538 Water-soluble dendritic unimole
Page 552 and 553:
540 Luo et al. (2002) demonstrated
Page 554 and 555:
Page 556 and 557:
544 IgE-receptor complexes, whereas
Page 558 and 559:
Page 560 and 561:
Page 563 and 564:
28 CONTENTS Dendrimer Nanocomposite
Page 565 and 566:
Dendrimer Nanocomposites for Cancer
Page 567 and 568:
Page 569 and 570:
Page 571 and 572:
Page 573 and 574:
Page 575 and 576:
Page 577 and 578:
Page 579 and 580:
Page 581 and 582:
Page 583 and 584:
Page 585 and 586:
Page 587 and 588:
Page 589 and 590:
Page 591 and 592:
Page 593 and 594:
Page 595 and 596:
Page 597 and 598:
Page 599 and 600:
Page 601 and 602:
Page 603 and 604:
Page 605 and 606:
29 CONTENTS Applications of Liposom
Page 607 and 608:
Applications of Liposomal Drug Deli
Page 609 and 610:
Page 611 and 612:
Page 613 and 614:
Page 615 and 616:
Page 617 and 618:
Page 619 and 620:
Page 621:
Page 624 and 625:
Page 626 and 627:
Page 628 and 629:
618 In many instances, the use of n
Page 630 and 631:
620 weight polymers to the liposome
Page 632 and 633:
Page 634 and 635:
624 uptake by healthy organ tissues
Page 636 and 637:
Page 639 and 640:
31 CONTENTS Cell Penetrating Peptid
Page 641 and 642:
CPP-Modified Liposomal Nanocarriers
Page 643 and 644:
Page 645 and 646:
Page 647 and 648:
Page 649 and 650:
Page 651:
Page 654 and 655:
644 Allen 1998), serum proteins (Br
Page 656 and 657:
646 cell; partial denuding of the e
Page 658 and 659:
648 to distinct, but often overlapp
Page 660 and 661:
650 TABLE 32.3 Integrin Receptors a
Page 662 and 663:
652 Basement Membrane Carcinoma Inv
Page 664 and 665:
654 YIGSR RGD distearoylphosphatidy
Page 666 and 667:
656 FIGURE 32.10 (See color insert
Page 668 and 669:
Page 670 and 671:
Page 673 and 674:
33 CONTENTS Folate Receptor-Targete
Page 675 and 676:
Folate Receptor-Targeted Liposomes
Page 677 and 678:
Page 679 and 680:
Page 681 and 682:
Page 683 and 684:
Page 685:
Page 688 and 689:
Page 690 and 691:
Page 692 and 693:
682 FIGURE 34.2 (a) A new paradigm
Page 694 and 695:
684 34.2.2 GETTING THE NANOCAPSULES
Page 696 and 697:
686 Expansion modulus K A mN/m 4000
Page 698 and 699:
688 (x) 90 min after injection' 1 m
Page 700 and 701:
Page 702 and 703:
692 Drug FIGURE 34.10 A tentative l
Page 704 and 705:
694 Thermal sensitive liposomes (TS
Page 706 and 707:
696 (a) (b) (c) 5 μm 1 μm 40 μm
Page 708 and 709:
698 - SO2 - SO2 - SO2 NBD - NBD - -
Page 710 and 711:
700 melting grain boundaries, formi
Page 712 and 713:
702 Percent of DOX released 100 90
Page 714 and 715:
704 Relative tumour volume (V/Vo )
Page 716 and 717:
706 (a) 0.6 LTSL-HT LTSL-DOX-HT LTS
Page 718 and 719:
708 differences in the levels of hy
Page 720 and 721:
710 trials, and preliminary indicat
Page 722 and 723:
712 encapsulated liposomal contents
Page 724 and 725:
Page 726 and 727:
Page 728 and 729:
Page 731 and 732:
35 CONTENTS Nanoemulsion Formulatio
Page 733 and 734:
Nanoemulsion Formulations for Tumor
Page 735 and 736:
Page 737 and 738:
Page 739 and 740:
Page 741 and 742:
Page 743 and 744:
Page 745 and 746:
Page 747:
Page 750 and 751:
742 36.5.5 Delivery of Chemosensiti
Page 752 and 753:
744 TABLE 36.1a Structures of Lipid
Page 754 and 755:
746 TABLE 36.3 Categories of Solid
Page 756 and 757:
748 Poly(ethylene oxide) (PEO) chai
Page 758 and 759:
750 FIGURE 36.3 Transmission electr
Page 760 and 761:
752 Cold homogenization method Melt
Page 762 and 763:
754 release kinetics of SLN and NLC
Page 764 and 765:
756 for lyophilization, the reconst
Page 766 and 767:
758 related work are listed in Tabl
Page 768 and 769:
760 improve its water solubility an
Page 770 and 771:
762 formulations. These include dox
Page 772 and 773:
764 36.5.5 DELIVERY OF CHEMOSENSITI
Page 774 and 775:
766 In other words, synergistic eff
Page 776 and 777:
768 FIGURE 36.15 Fluoroescence micr
Page 778 and 779:
770 because of the presence of the
Page 780 and 781:
Page 782 and 783:
Page 784 and 785:
Page 786 and 787:
778 Phospholipid Unesterified chole
Page 788 and 789:
Page 790 and 791:
782 via receptor-mediated mechanism
Page 792 and 793:
Page 795 and 796:
38 CONTENTS DQAsomes as Mitochondri
Page 797 and 798:
DQAsomes as Mitochondria-Targeted N
Page 799 and 800:
Page 801 and 802:
Page 803 and 804:
Page 805 and 806:
Page 807 and 808:
Page 809 and 810:
Page 811:
Section 1 Nanotechnology and Cancer
Page 815:
Section 3 Polymeric Nanoparticles q
Page 819:
Section 5 Dendritic Nanocarriers q
Page 823:
Section 7 Other Lipid Nanostructure
show all

q 2006 by Taylor & Francis Group, LLC - Developers

Create successful ePaper yourself

Delete template?

Save as template?